Proposed mechanism of distal, G4-mediated regulation of gene expression in drug-resistant ovarian cancer cells. Credit: Genome Biology (2025). DOI: 10.1186/s13059-025-03654-y

An unusual DNA structure may hold the key to treating one of the deadliest cancers affecting women, which claims more than 200, 000 lives globally each year.

Most women with ovarian cancer respond very well to chemotherapy at first—but in 70% of cases the cancer grows back. And although many patients will respond to chemotherapy a second or third time, eventually the drugs will stop having an effect.

In a new study led by Institute of Chemical Biology-CDT Ph.D. students Gem Flint and Dr. Jenna Robinson and published in Genome Biology, researchers reveal how four-stranded DNA structures, known as G-quadruplexes, could be targeted to reverse chemoresistance in ovarian cancer. This approach could potentially restore the effectiveness of chemotherapy in patients who no longer respond to treatment.

"It's been a fantastic opportunity to work on such an exciting project as part of my Ph.D., " said Gem Flint. "Chemotherapy resistance is a major challenge for ovarian cancer patients, so having the opportunity to contribute to the scientific understanding of how this resistance may develop has been incredibly rewarding."

These findings led to collaborative research led by Dr. Marco Di Antonio (Department of Chemistry) with Professor Hector Keun and Professor Iain McNeish (Department of Surgery & Cancer) at Imperial College London, who now head the team working to translate these insights into new treatment strategies.

While most DNA exists in the familiar double helical form, it can also adopt alternative configurations under certain conditions. One such structure, rare but functionally significant, is the quadruple helical structure known as G-quadruplex. These four-stranded DNA arrangements were initially thought to be only a structural oddity.

Dr. Jenna Robinson commented, "It's incredibly exciting to understand more about how cancer cells become resistant to drugs. Drug resistance has been a major challenge in cancer treatment for decades, and while we've learned a lot, cancers continue to surprise us with the many ways they adapt and evolve."

In recent years, researchers, including the Imperial team, verified that G-quadruplex DNA structures occur naturally in living human cells, particularly within regions that control gene expression. Building on this foundation, Flint and Robinson investigated the functional role of these structures in ovarian cancer cells, analyzing how tumor cells change as they become resistant to chemotherapy.

They found that G-quadruplexes tend to accumulate in resistant cancer cells, forming within new regions of the genome, where enrichment of these structures was never observed before. DNA G-quadruplexes appear to substantially help ovarian cancer cells activate genes that counteract chemotherapy, effectively shielding the tumor from treatment.

But the researchers also discovered their presence as a potential weakness. Indeed, by targeting the G-quadruplexes with specialized drugs, they were able to re-sensitize the resistant cells to standard therapies, thereby restoring the vulnerability of resistant cancer cells to chemotherapy.

Dr. Marco Di Antonio stated, "This is an exciting discovery. For over a decade, we've known that G-quadruplex DNA can form in the genome, but this is the first time we've observed a functional response linked to targeting these structures—one that could be harnessed for therapeutic applications.

"With top ovarian cancer specialists at Imperial just down the road, we can now fast-track investigating if these promising results can benefit patients."

This research provides a promising new approach to treating patients with relapsed ovarian cancer and adds to growing evidence that DNA's alternative structures could be powerful targets in the fight against diseases like cancer and neurodegeneration. The team is now working to establish if other cancers also harness DNA G-quadruplex structures to become resistant to chemotherapy, extending the relevance of this discovery.

More information: Jenna Robinson et al, G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer cells, Genome Biology (2025). DOI: 10.1186/s13059-025-03654-y  Journal information: Genome Biology